甲氨蝶呤治疗银屑病的系统评价
作者：胡蝶;兰瑛;宋海宁;王永莉;黄师婧;邹波;黄心一;何琴;
Author：
收稿日期： 年卷（期）页码：2015,30(05):-623-626
期刊名称：华西药学杂志
Journal Name：WEST CHINA JOURNAL OF PHARMACEUTICAL SCIENCES
关键字：甲氨蝶呤;银屑病;有效性;安全性;系统评价;Meta分析;疗效
Key words：
基金项目：“十二五”国家科技支撑计划课题(编号:2013BAI06B04)
中文摘要
目的系统评价甲氨蝶呤(MTX)治疗银屑病的有效性及安全性。方法用计算机检索4个中文数据库及4个英文数据库,检索时间截止至2013年8月,数据被纳入研究MTX治疗银屑病疗效及安全性的随机对照实验(RCT),采用Rev Man5.0.2软件进行Meta分析或描述性分析。结果纳入RCT 10个(12篇研究),其中9篇研究MTX治疗斑块型银屑病的疗效。在治疗中重度斑块型银屑病中,MTX与其他免疫抑制剂比较,疗效低于来氟米特,与吗替麦考酚酯、硫唑嘌呤疗效相似,与环孢素比较结论存在差异;与肿瘤坏死因子拮抗剂比较,MTX的疗效低于阿达木单抗、英夫利昔单抗。MTX治疗中重度寻常型银屑病的疗效低于重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白。口服MTX的不良反应发生率高,但主要为轻中度不良反应。结论 MTX治疗中重度斑块型银屑病安全有效,结论还需高质量、多中心、大样本的研究证实。
参考文献
[1]赵娜,吴卫志,杨平.银屑病流行病学研究进展[J].山东医药,2013,53(39):95-97.
[2]全国银屑病流行调查组.全国1984年银屑病流行调查报告[J].皮肤病与性病,1989,(01):60-72.
[3]张建中.银屑病的流行病学与危险因素[J].实用医院临床杂志,2013,10(1):4-6.
[4]中华医学会皮肤性病学分会银屑病学组.中国银屑病治疗指南(2008版)[J].中华皮肤科杂志,2009,42(3):213-214.
[5]Higgins J,Green S.Cochrane handbook for systematic reviews of interventions version 5.0.2[updated September 2009][J].The Cochrane Collaboration,2009.Available from:www.cochranehandbook.org.2010.
[6]Ho SG,Yeung CK,Chan HH.Methotrexate versus traditional Chinese medicine in psoriasis:A randomized,placebo-controlled trial to determine efficacy,safety and quality of life[J].Clin Exp Dermatol,2010,35(7):717-722.
[7]Saurat JH,Stingl G,Dubertret L,et al.Efficacy and safety results from the randomized controlled comparative study of adalimumab vs.methotrexate vs.placebo in patients with psoriasis(CHAMPION)[J].Br J Dermatol,2008,158(3):558-566.
[8]Flytstrom I,Stenberg B,Svensson A,et al.Methotrexate vs.ciclosporin in psoriasis:effectiveness,quality of life and safety.A randomized controlled trial[J].Br J Dermatol,2008,158(1):116-121.
[9]Heydendael VM,Spuls PI,Opmeer BC,et al.Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis[J].New England J Med,2003,349(7):658-665.
[10]Bhuiyan MSI,Sikder Md A,Rashid MM,et al.Role of oral colchicine in plaque type psoriasis:A randomized clinical trial comparing with oral methotrexate[J].JPAD,2010,20:146-151.
[11]Ali ME,Rahman GMM,Akhtar N,et al.Efficacy and safety of leflunomide in the treatment of plaque type psoriasis[J].JPAD,2009,19:18-22.
[12]Akhyani M,Chams-Davatchi C,Hemami MR,et al.Efficacy and safety of mycophenolate mofetil vs.methotrexate for the treatment of chronic plaque psoriasis[J].J Eur Acad of Dermatology&Venereology,2010,24(12):1447-1451.
[13]Malik T,Ejaz A.Comparison of methotrexate and azathioprine in the treatment of psoriasis:A randomized controlled trial[J].JPAD,2010,20:152-157.
[14]Barker J,Hoffmann M,Wozel G,et al.Efficacy and safety of infliximab vs.methotrexate in patients with moderate-to-severe plaque psoriasis:Results of an open-label,active-controlled,randomized trial(RESTORE1)[J].Br J Dermatol,2011,165(5):1109-1117.
[15]黄琼,杨勤萍,方棚,等.重组人Ⅱ型肿瘤坏死因子受体一抗体融合蛋白治疗寻常性银屑病多中心、随机、双盲试验[J].中华皮肤科杂志,2007,40(11):655-658.
[16]Reich K,Langley RG.,Papp KA,et al.A 52-week trial comparing briakinumab with methotrexate in patients with psoriasis[J].N Engl J Med,2011,365(17):1586-1596.
[17]Dogra S,Krishna V,Kanwar AJ.Efficacy and safety of systemic methotrexate in two fixed doses of 10 mg or 25 mg orally once weekly in adult patients with severe plaque-type psoriasis:A prospective,randomized,double-blind,dose-ranging study[J].Clin Exp Dermatol,2012,37(7):729-734.
[18]Fallah Arani S,Neumann H,Hop WC,et al.Fumarates vs.methotrexate in moderate to severe chronic plaque psoriasis:A multicentre prospective randomized controlled clinical trial[J].Br J Dermatol,2011,164(4):855-861.
[19]Radmanesh M,Rafiei B,Moosavi ZB,et al.Weekly vs.daily administration of oral methotrexate(MTX)for generalized plaque psoriasis:A randomized controlled clinical trial[J].Int J Dermatol,2011,50(10):1291-1293.
[20]Kingsley GH,Kowalczyk A,Taylor H,et al.A randomized placebo-controlled trial of methotrexate in psoriatic arthritis[J].Rheumatology(Oxford),2012,51(8):1368-1377.
[21]Benoit S,Hamm H.Psoriasis in childhood and adolescence:Clinical features and therapy[J].Hautarzt,2009,60(2):100-108.
【关闭】
